Omeros initiated with a Buy at D. Boral Capital

D. Boral Capital initiated coverage of Omeros (OMER) with a Buy rating and $36 price target With Narsoplimab now poised for U.S. approval, followed by Europe, Omeros is “at an inflection point,” argues the analyst, who sees the upcoming resubmission of Narsoplimab’s Biologics License Application for thrombotic microangiopathy associated with transplantation as “just the beginning of Omeros’ transition to a fully integrated ethical pharma company.” FDA approval will make Narsoplimab the first and only approved treatment for TA-TMA, notes the firm, which also believes “strongly in the other products in the company’s pipeline,” but bases its valuation only on Narsoplimab.